Materials Today今日材料
Materials Today(英文缩写 MATER TODAY),ISSN 1369-7021,eISSN 1873-4103,中文译名:今日材料 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 26.943 | Q1 |
| 2022 | 24.200 | Q1 |
| 2023 | 21.100 | Q1 |
| 2024 | 22.000 | Q1 |
| 2025 | 24.100 | Q1 |
Materials Today 最新收录文献
-
1. Bioactive lipid-derived nanoparticles for RNA delivery.
1. 用于RNA递送的生物活性脂质衍生纳米颗粒PMID:日期:2026-08-18Lipid nanoparticles (LNPs) have emerged as the most widely used and clinically validated platform for delivering RNAs, including small interfering RNA (siRNA) and messenger RNA (mRNA), as exemplified by the FDA approvals of Onpattro, Comirnaty, Spikevax, and mRESVIA. LNPs offer various benefits for RNA delivery, such as protecting RNA from enzymatic degradation, increasing cellular uptake and endosomal escape, and improving pharmacokinetics. To further broaden their use across a wide spectrum of diseases, various LNPs have recently been developed with unique biological functions, such as immunomodulation, tissue microenvironmental modulation, endosomal pathway interference, pharmacological activity, and tissue and cell selectivity, giving rise to the emerging concept of bioactive lipid-derived nanoparticles (bioactive LNPs). In this review, we summarize bioactive LNPs incorporating naturally sourced bioactive lipids, bioactive agent-derived lipids, or novel bioactive lipids identified through combinatorial synthesis coupled with high-throughput screening. We also discuss the structure-activity relationship of these bioactive lipids and overview their corresponding LNPs for specific biomedical applications. We further provide perspectives on the challenges and opportunities in translating bioactive lipid-derived LNPs into next-generation RNA nanomedicines.
-
2. Imidazolium Lipid-based Nanoparticles Enable Effective mRNA Delivery and Cellular Immune Response.
PMID:日期:2026-03-05Imidazolium LipidBrick cationic lipid nanoparticles (LNPs) provide a pH-independent alternative to conventional ionizable systems for nucleic acid delivery. Through a high-throughput screen of 1,944 formulations spanning eight imidazolium cores, three helper lipids, and varying PEG densities, we found that more than half of the library outperformed the clinical ionizable benchmark ALC-0315 in multiple representative mammalian cell types. Top-performing candidates showed robust cellular uptake, efficient endosomal escape, and strong transgene expression both and following intramuscular administration. A lead formulation (C3 LNP), incorporating an imidazolium lipid core bearing a hydroxyethyl substituent, with 30 mol% DOPE, achieved comparable intramuscular luciferase expression and antibody titers to ALC-0315, while eliciting ~3-fold stronger ovalbumin-specific IFN-γ T-cell responses and maintaining low cytotoxicity. Machine-learning analysis of the dataset further distilled transferable design rules to inform future formulation strategies. Collectively, these findings establish cationic LipidBrick LNPs as a versatile platform for mRNA delivery, offering a generalizable framework for the high-throughput discovery of ionization-independent systems that effectively prime adaptive immune responses.
-
3. Biodegradable lipid nanoparticles for genome editing in the brain via intrathecal administration.
PMID:日期:2026-01-23Messenger RNA (mRNA)-based nonviral delivery of gene editors offers transformative potential for therapeutic genome editing in neurological diseases, but efficient and safe delivery to the brain remains a formidable challenge due to the restrictive blood-brain barrier. Intrathecal administration provides a clinically validated route to bypass this barrier, yet the design principles for biodegradable lipid nanoparticles (LNPs) optimized for central nervous system (CNS) delivery remain poorly defined. Here, we synthesized a 200-member combinatorial library of structurally diverse, biodegradable ionizable lipids using the Passerini three-component reaction. High-throughput screening identified P3B, a lead lipid incorporating degradable linkages and optimized ionizable head groups, which enables potent and well-tolerated intrathecal mRNA delivery. In Ai9 reporter mice, P3B-LNPs encapsulating Cas9 mRNA/sgRNA induced robust and widespread tdTomato expression in neurons and astrocytes across multiple brain regions, achieving substantially higher editing efficiency than the clinical benchmark DLin-MC3-DMA (MC3). In LumA reporter mice, P3B-LNPs mediated efficient adenine base editing, restoring luciferase expression throughout the brain with 14.8% on-target correction and minimal off-target activity. Compared with MC3, P3B-LNPs exhibited enhanced tolerability, with attenuated inflammatory responses and a safety profile supportive of repeated dosing. These findings establish P3B-LNPs as a potent, safe, and biodegradable platform for genome editing in the brain and underscore the power of combinatorial lipid chemistry and high-throughput screening to accelerate the development of next-generation LNPs for CNS-targeted mRNA therapeutics.
-
4. Engineering bone tissue with mRNA: from molecular design and delivery to clinical applications.
PMID:日期:2025-12-05Bone possesses an intrinsic ability to regenerate after injury, but this capacity is often compromised in pathological conditions. Non-healing fractures are typically treated with autografts, which involve additional surgeries, patient discomfort, and risk of complications. Alternative strategies, such as the administration of growth factor proteins or plasmid DNA, have shown promise but are limited by high costs, immunogenicity, and safety concerns. Recently, messenger RNA (mRNA) therapies have emerged as a compelling alternative for inducing bone regeneration. Unlike DNA, mRNA functions in the cytoplasm, eliminating the need for nuclear entry and minimizing the risk of insertional mutagenesis. It is also transiently expressed and fully degradable, offering a favorable safety profile. Chemical modifications to mRNA can improve its stability, translational efficiency, and reduce innate immune activation, making it a versatile and potent tool for therapeutic applications. In this review, we explore the types of chemical modifications used to enhance mRNA performance, the delivery strategies employed for efficient cellular uptake (including and routes), and the design of biomaterial scaffolds that support bone repair while enabling spatial and temporal control of gene expression. We also discuss the translational potential of mRNA-based approaches, including safety considerations, manufacturing scalability, and cost-effectiveness. Collectively, these advances position chemically modified mRNA as a next-generation therapeutic for bone regeneration, with the potential to overcome the limitations of current treatments and improve outcomes for patients with challenging fractures.
-
5. Aminophosphonate-Derived Lipid Nanoparticles Enable Circular RNA Delivery for Functional Recovery after Spinal Cord Injury.
5. 氨基膦酸酯衍生的脂质纳米粒能够实现循环RNA递送，以促进脊髓损伤后的功能恢复PMID:日期:2025-10-16Spinal cord injury (SCI) is a devastating neurological disorder that results in severe disability and imposes a high social and economic burden. Effective recovery from SCI requires comprehensive neural repair strategies, including neurogenesis and neuroprotection. Inspired by the structure of phospholipids in nature, we developed a library of biomimetic ionizable lipids, containing aminophosphate, aminophosphoramidate, or aminophosphonate groups (AP lipids). Then, we formulated these AP lipids into lipid nanoparticles (LNPs) and examined their mRNA delivery efficiency in neurons and astrocytes. Among these AP LNPs, AP60 LNP showed superior delivery efficiency compared to FDA approved D-Lin-MC3-DMA (MC3) LNP. To achieve longer protein expression, the circular RNA was used in LNPs. Additionally, we developed a two-step method for circular RNA production, providing a simple yet highly efficient approach. By combining these innovations, a circular RNA loaded aminophosphonate-derived lipids nanoparticles delivery system (CROSS) was constructed. To explore a therapeutic regimen, CROSS-loaded with circular Sox2, Ascl1, and GDNF RNAs were administered locally and intravenously in SCI model, which led to the restoration of bladder function and significant motor function recovery. In summary, the CROSS platform provided a novel and effective strategy for treating SCI.
-
6. Aptamers in Drug Delivery Development.
6. 药物递送开发中的适配体PMID:日期:2025-08-14Aptamers, often described as "chemical antibodies", are short, single-stranded nucleic acids that can bind target molecules with high affinity and specificity. Due to these properties, aptamers have diverse therapeutic applications. They can function as standalone drugs, serve as carriers for a range of therapeutics including small molecules, nucleic acids, peptides, proteins, and antibodies, or be used to functionalize drug delivery systems such as nanoparticles and bulk biomaterials. This review summarizes these diverse applications and discusses potential challenges associated with aptamers and drug delivery systems more broadly.
-
7. Biofabrication of engineered tissues by 3D bioprinting of tissue specific high cell-density bioinks.
PMID:日期:2025-05-16Bioprinting of high cell-density bioinks is a promising technique for cellular condensation-based tissue engineering and regeneration medicine. However, it is still difficult to create precisely controlled complex structures and organization of tissues with high cell-density bioink-based bioprinting for tissue specific condensation. In this study, we present newly biofabricated tissues from directly assembled, tissue specific, high cell-density bioinks which have been three-dimensionally printed into a photocrosslinkable and biodegradable hydrogel microparticle supporting bath. Three types of tissue specific high cell-density bioinks have been prepared with individual stem cells or stem cell aggregates by incorporation of growth factor-loaded gelatin microparticles. The bioprinted tissue specific high cell-density bioinks in the photocrosslinked microgel supporting bath condense together and differentiate down tissue-specific lineages to form multi-phase tissues (e.g., osteochondral tissues). By changing the growth factors and cell types, these tissue specific high cell-density bioinks enable engineering of various functional tissues with controlled architecture and organization of cells.
-
8. Next-generation health monitoring: The role of nanomaterials in 3D-printed wearable devices.
PMID:日期:2025-05-16Wearable devices have made transformative advancements driven by the integration of nanomaterials, enhancing their versatility, sensitivity, and overall performance. The emerging 3D printing techniques revolutionize traditional fabrication, enabling the high-efficiency fabrication for sophisticated and miniaturized healthcare monitoring systems. This review summarizes the essential properties of nanomaterials and their roles in 3D printing and examines the pros and cons of various 3D printing methods. Key applications of 3D-printed wearable devices, showcasing the synergistic contributions of nanomaterials, are introduced to provide a comprehensive overview of the state-of-the-art progress and the promising prospects for next-generation healthcare monitoring.
-
9. New block copolymers to form nanofibers with superior mechanical properties and to conjugate signaling molecules directing tissue regeneration.
PMID:日期:2025-05-16Tissue engineering is a multidisciplinary field grown rapidly over the past few decades, whose success most often requires bioactive scaffolds to structurally support and biologically direct cell fate and tissue regeneration. Poly(l-lactic acid) (PLLA) is a widely used tissue engineering material with high strength, biocompatibility, biodegradability, and the capability of nanofiber formation through thermally induced phase separation (TIPS). To enable biomolecule conjugation, a new PLLA-based block copolymer, poly(spiro lactic-co-lactic acid)-block-poly(l-lactic acid) or PSLA-b-PLLA, was developed in this study. The new polymer PSLA-b-PLLA could also form nanofibers through TIPS, and excitingly greatly improved the mechanical properties over PLLA nanofibers, with up to 1.2 times tensile modulus, 12.1 times strain at break, 2.1 times ultimate strength and 35.1 times toughness of PLLA, while being able to conjugate bioactive molecules covalently using click reactions. Its degradation rate was also accelerated to facilitate tissue regeneration. The tissue engineering potential of the new polymer scaffold was evaluated using a mouse critical-sized bone regeneration model, showing 3.6 times more vascularized bone volume regeneration when covalently conjugated with a bone-morphogenetic-protein-2-derived peptide. The block copolymer satisfies multiple criteria for tissue engineering with tunable mechanical properties, degradation rate, and conjugation densities. It can be utilized to impart specific biomolecular signals and mechanical properties potentially for various other tissue engineering applications.
-
10. Lymph Node-Targeted Cyclosporine A Alleviates Myocarditis in Lupus Mice by Inhibiting CD68+ Macrophage-Driven Lymphangiogenesis.
PMID:日期:2025-05-16Lupus myocarditis, a severe and often underdiagnosed complication of systemic lupus erythematosus (SLE), remains challenging to treat due to the complex inflammatory processes involved. While lymphangiogenesis has been implicated in lupus nephritis, its role in myocarditis is not well understood. This study investigates the potential of lymph node-targeted cyclosporine A (CsA) as a therapeutic approach for lupus myocarditis. Using a lupus mouse model, we explored the effects of localized immunosuppression through polymer nanoparticles designed to deliver CsA with lymph node-targeting functionality (P2Ns-GA-CsA), CsA without targeting (P2Ns-CsA), and a commercial CsA formulation as controls. Our results demonstrate that P2Ns-GA-CsA significantly alleviates inflammation in lupus myocarditis, as evidenced by a reduction in macrophage infiltration (CD68+ cells) and lower levels of pro-inflammatory cytokines. Histological analysis revealed improvements in cardiac function and a decrease in myocardial fibrosis. Moreover, P2Ns-GA-CsA inhibited pathological lymphangiogenesis by downregulating VEGF-C and VEGFR3 expression, restoring lymphatic vessel density. Additionally, treatment enhanced PGC1α signaling, improving metabolic regulation and further suppressing inflammation. This study highlights the involvement of inflammation-driven lymphangiogenesis in lupus myocarditis and demonstrates that P2Ns-GA-CsA provides superior anti-inflammatory, cardioprotective, and anti-lymphangiogenic effects. These findings suggest that targeted immunosuppressive therapies could offer a promising strategy for managing cardiovascular complications in lupus.